| Literature DB >> 24376838 |
Yeqiang Liu1, Cheng Jin2, Aijun Xing2, Xiurong Liu2, Shuohua Chen2, Dongqing Li2, Ping Feng3, Jinquan Liu3, Zhiguo Li4, Shouling Wu2.
Abstract
OBJECTIVE: To prospectively investigate the association between serum uric acid (SUA) level and incidence of impaired fasting glucose (IFG) in adult Chinese.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24376838 PMCID: PMC3871632 DOI: 10.1371/journal.pone.0084712
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the population by gender and quintile of uric acid in the Kailuan Study in 2006-2010.
| Uric acid quintile | |||||
|---|---|---|---|---|---|
| Quintile 1 | Quintile 2 | Quintile3 | Quintile4 | Quintile5 | |
|
| |||||
| No. of patient | 2644 | 2682 | 2659 | 2639 | 2704 |
| Uric acid, µmol/L | <186.6 | 187.0-217.9 | 218.0-248.9 | 249.0-289.0 | >289.0 |
| Uric acid Median, µmol/L | 162.0 | 203.0 | 232.0 | 267.0 | 324.5 |
| Age, year | 45.3±10.1 | 45.2±10.3 | 46.0±10.8 | 47.3±11.1 | 50.3±12.8 |
| SBP, mmHg | 118.0±18.3 | 119.0±18.5 | 121.0±19.3 | 122.0±20.3 | 126.0±20.7 |
| DBP, mmHg | 76.9±10.3 | 77.5±10.4 | 77.9±10.6 | 78.8±10.8 | 79.7±10.0 |
| BMI, kg/m2 | 23.3±3.4 | 23.7±3.4 | 24.1±3.6 | 24.6±3.6 | 25.3±3.8 |
| TG, mmol/L | 1.1±0.8 | 1.2±0.8 | 1.3±0.9 | 1.4±1.0 | 1.7±1.2 |
| TC, mmol/L | 4.8±1.0 | 4.8±1.0 | 4.8±1.0 | 5.0±1.0 | 5.1±1.1 |
| HDL-C, mmol/L | 1.5±0.4 | 1.6±0.4 | 1.6±0.4 | 1.6±0.4 | 1.6±0.4 |
| LDL-C, mmol/L | 2.1±1.0 | 2.1±0.9 | 2.2±0.8 | 2.3±0.8 | 2.2±0.8 |
| FBG, mmol/L | 4.7±0.5 | 4.8±0.5 | 4.8±0.5 | 4.8±0.5 | 4.7±0.5 |
| Log CRP | -0.6±1.6 | -0.6±1.5 | -0.5±1.5 | -0.3±1.4 | 0.1±1.4 |
| Medical history | |||||
| Hypertension, % | 4.3 | 5.4 | 6.9 | 9.3 | 19.8 |
| Use of Antihypertensives, % | 3.6 | 4.8 | 6.1 | 8.3 | 18.7 |
| Hyperlipidemia, % | 2.5 | 2.9 | 4.3 | 5.7 | 12.1 |
| Use of Antihyperlipidemia, % | 0.3 | 0.3 | 0.5 | 0.8 | 2.8 |
| Smoking | |||||
| never, % | 98.4 | 98.8 | 98.0 | 98.1 | 96.9 |
| former, % | 0.2 | 0.3 | 0.2 | 0.3 | 0.6 |
| current, % | 1.3 | 0.9 | 1.8 | 1.6 | 2.6 |
| Alcohol drinking | |||||
| never, % | 93.0 | 93.7 | 92.4 | 91.9 | 91.0 |
| former, % | 0.5 | 0.4 | 0.3 | 0.5 | 0.5 |
| current, % | 6.5 | 5.9 | 7.3 | 7.6 | 8.5 |
|
| |||||
| No. of patient | 8117 | 8290 | 8297 | 8265 | 8381 |
| Uric acid, µmol/L | <233.9 | 234.0-275.0 | 275.0-312.9 | 313.0-362.0 | >362.0 |
| Uric acid Median, µmol/L | 207.6 | 256.0 | 293.0 | 334.0 | 403.0 |
| Age, year | 49.3±11.8 | 49.7±12.0 | 50.0±12.4 | 49.8±12.8 | 50.6±13.5 |
| SBP, mmHg | 129.0±18.7 | 128.0±19.2 | 129.0±19.6 | 129.0±19.6 | 131.0±20.1 |
| DBP, mmHg | 83.2±11.0 | 82.8±11.2 | 83.2±11.4 | 83.2±11.4 | 84.7±11.7 |
| BMI, kg/m2 | 24.3±3.3 | 24.3±3.2 | 24.3±3.3 | 25.1±3.3 | 25.9±3.4 |
| TG, mmol/L | 1.5±1.1 | 1.5±1.1 | 1.5±1.2 | 1.6±1.3 | 2.0±1.5 |
| TC, mmol/L | 4.6±1.2 | 4.8±1.1 | 4.9±1.0 | 5.0±1.1 | 5.1±1.1 |
| HDL-C, mmol/L | 1.6±0.4 | 1.6±0.4 | 1.5±0.4 | 1.5±0.4 | 1.5±0.4 |
| LDL-C, mmol/L | 2.3±0.9 | 2.3±0.9 | 2.3±0.9 | 2.4±0.8 | 2.3±0.9 |
| FBG, mmol/L | 4.8±0.5 | 4.8±0.5 | 4.8±0.5 | 4.8±0.5 | 4.8±0.5 |
| Log CRP | -0.5±1.7 | -0.5±1.6 | -0.4±1.5 | -0.3±1.7 | -0.1±1.4 |
| Medical history | |||||
| Hypertension, % | 4.9 | 6.6 | 8.7 | 10.1 | 16.2 |
| Use of Antihypertensives, % | 4.0 | 5.5 | 7.4 | 8.8 | 14.5 |
| Hyperlipidemia, % | 2.2 | 2.6 | 3.8 | 4.7 | 7.4 |
| Use of Antihyperlipidemia, % | 0.3 | 0.3 | 0.5 | 0.6 | 1.0 |
| Smoking | |||||
| never, % | 60.8 | 52.7 | 49.7 | 44.8 | 40.2 |
| former, % | 4.4 | 5.2 | 5.9 | 6.9 | 8.6 |
| current, % | 34.8 | 42.0 | 44.4 | 48.3 | 51.2 |
| Alcohol drinking | |||||
| never, % | 62.5 | 55.2 | 49.5 | 42.9 | 35.3 |
| former, % | 3.0 | 3.5 | 4.0 | 3.9 | 4.5 |
| current, % | 34.5 | 41.3 | 46.5 | 53.2 | 60.2 |
* Logarithmic transformed values for hsCRP.
Hazard ratios (HRs) and 95% confidence interval (CI) for risk of new onset Impaired Fasting Glucose according to serum uric acid quintile among individuals in the Kailuan Study in 2006-2010.
| Uric acid quintile | |||||
|---|---|---|---|---|---|
| Quintile 1 | Quintile 2 | Quintile3 | Quintile4 | Quintile5 | |
|
| |||||
| Case, n | 547(20.7%) | 577(21.5%) | 611(23.0%) | 668(25.3%) | 812(30.0%) |
| Model 1 | 0.97(0.86-1.10) | 1.00 | 1.03(0.91-1.15) | 1.08(0.96-1.21) | 1.10(0.98-1.22) |
| Model 2 | 0.99(0.88-1.12) | 1.00 | 0.96(0.85-1.08) | 1.03(0.91-1.15) | 1.02(0.91-1.14) |
| Model 3 | 0.99(0.87-1.11) | 1.00 | 0.97(0.86-1.09) | 1.03(0.92-1.15) | 1.02(0.91-1.14) |
|
| |||||
| Case, n | 2617(32.2%) | 2482(29.9%) | 2666(32.1%) | 2804(33.9%) | 2982(35.6%) |
| Model 1 | 1.11(1.06-1.18) | 1.00 | 1.07(1.00-1.10) | 1.12(1.06-1.18) | 1.12(1.06-1.18) |
| Model 2 | 1.11(1.05-1.17) | 1.00 | 1.04(0.98-1.10) | 1.07(1.02-1.14) | 1.03(0.98-1.09) |
| Model 3 | 1.11(1.05-1.17) | 1.00 | 1.03(0.98-1.09) | 1.07(1.01-1.13) | 1.02(0.97-1.08) |
Note: Model 1, adjusted for age (year).
Model 2, adjusted for age (year), SBP(mmHg), DBP(mmHg), BMI(kg/m2), TG(mmol/L), TC(mmol/L), HDL-C(mmol/L), LDL-C(mmol/L), FBG(mmol/L), log CRP(mg/L), hypertension(yes/no), use of antihypertensives(yes/no, including diuretics, beta-blockers, alpha-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, and angiotensin II receptor blockers), hyperlipidemia(yes/no), and use of Antihyperlipidemia (yes/no).
Model 3, adjusted for age (year), SBP(mmHg), DBP(mmHg), BMI(kg/m2), TG(mmol/L), TC(mmol/L), HDL-C(mmol/L), LDL-C(mmol/L), FBG(mmol/L), log CRP(mg/L), hypertension(yes/no), use of antihypertensives(yes/no, including diuretics, beta-blockers, alpha-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, and angiotensin II receptor blockers), hyperlipidemia(yes/no), use of antihyperlipidemia (yes/no), smoking (never/former/current), and alcohol drinking (never/former/current).